Past Podcast Episodes

We've been using the same MS clinical course descriptors (relapsing-remitting, secondary progressive, and primary progressive) for almost three decades. As research has provided so much additional information and insight, is it time to update the way we describe, diagnose, and treat MS?

The International Advisory Committee on Clinical Trials in Multiple Sclerosis has established a working group to explore this question. And, as a means of eliciting feedback from stakeholders around the world, a global survey was launched.

The National MS Society's Chief Advocacy, Services, and Science Officer, Dr. Tim Coetzee, joins me to share the results of this survey, which may represent a first step toward delivering next-generation MS care.

Tim Coetzee

We're just two days away from the Hispanic/Latinx MS Experience Summit! We'll tell you why you don't want to miss this free online event, and we'll even tell you how to register.

We're sharing the results of a study that provides strong evidence for adopting hematopoietic stem cell transplantation (aHSCT) as a standard treatment option for people living with relapsing-remitting MS.

And we're sharing evidence from a Phase 3 clinical trial that demonstrates how cognitive behavioral therapy delivered over the internet significantly reduces depressive symptoms and improves the quality of life for people with MS.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: When it comes to adopting a new framework for describing MS, the survey says… :22

The Hispanic-Latinx MS Experience Summit is just two days away! 2:02

Swedish study shows that autologous hematopoietic stem cell transplantation (aHSCT) is an effective treatment for adults with relapsing-remitting MS 3:41

Phase 3 clinical trial shows that cognitive behavioral therapy delivered over the internet significantly reduces depressive symptoms among people liviing with MS 6:07

Dr. Tim Coetzee shares the results of a global survey that asked whether it's time to update the way we describe, diagnose, and treat MS 9:36

Share this episode 27:21

Have you downloaded the free RealTalk MS app? 27:42

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/319

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Do the Current MS Clinical Course Descriptors Need to Change and If So, How?: A Survey of the MS Community
https://journals.sagepub.com/doi/10.1177/13524585231196786

RealTalk MS Episode 280: How the Proposed Framework for Diagnosing and Treating MS Will Affect You with Dr. Tim Coetzee
https://realtalkms.com/280

Register for the Hispanic/Latinx MS Experience Summit
https://nationalmssociety.org/Resources-Support/Library-Education-Programs/Hispanic-Latinx-MS-Experience-Summit

STUDY: Heaematopoietic Stem Cell Transplantation for Treating Multiple Sclerosis in Sweden: An Observational Cohort Study
https://jnnp.bmj.com/content/early/2023/08/14/jnnp-2023-331864

National MS Society Recommendations for aHSCT-Bone Marrow Transplant for MS
https://www.nationalmssociety.org/About-the-Society/News/National-MS-Society-Releases-Recommendations-for-a

STUDY: Internet-Derived Cognitive Behavioural Therapy Programme to Reduce Depressive Symptoms in Patients with Multiple Sclerosis: A Multicentre, Randomised, Controlled Phase 3 Trial
https://sciencedirect.com/science/article/pii/S2589750023001097

Join the RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

Download the RealTalk MS App for iOS Devices
https://itunes.apple.com/us/app/realtalk-ms/id1436917200

Download the RealTalk MS App for Android Devices
https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk

Give RealTalk MS a rating and review
http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 319
Guest: Dr. Tim Coetzee

Privacy Policy

In this episode of RealTalk MS, we're talking about what you should be talking about with your neurologist or MS Specialist. Shared decision-making is a key component of patient-centered health care. It's a process in which clinicians and patients work together to make evidence-based decisions on tests, treatments, and care plans that balance risks and expected outcomes with patient preferences and values.

But is shared decision-making actually occurring? Or are people living with MS still being handed a bunch of pamphlets published by different pharmaceutical companies and being asked to read them and let their doc know which disease-modifying therapy they'd like to start? How do we bridge the gap between the promise of shared decision-making and what, for too many people living with MS, is still an unfortunate reality?

Dr. Lilyana Amezcua joins me to share her thoughts on how to start the kinds of conversations you should be having with your neurologist or MS specialist.

Dr. Lilyana Amezcua

Dr. Amezcua is an Associate Professor of Neurology, a diversity, equity, and inclusion champion, and the fellowship program director at the University of Southern California Keck School of Medicine.

The National MS Society is hosting the second annual Hispanic/Latinx MS Experience Summit next week. We're sharing all the details, and we'll tell you how you can register for this free virtual event.

We'll fill you in on the European Medicine Agency's approval of the first biosimilar for treating MS.

And we're sharing the results of an important study that focused on how COVID mRNA vaccines affect people living with MS.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Getting shared decision-making right :22

The Hispanic/Latinx MS Experience Summit is happening Oct. 12th! 2:10

EMA approves the first biosimilar to treat MS 3:54

Study focuses on the affect of COVID mRNA vaccines on people living with MS 4:39

Dr. Lilyana Amezcua discusses how to make shared decision-making work for you and your neurologist 8:57

Share this episode 34:35

Have you downloaded the free RealTalk MS app? 34:55

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/318